Trial Profile
A multi-centre, double-blind, randomised-withdrawal, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR (TM)) as monotherapy in the maintenance treatment of patients with major depressive disorder.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Aug 2019
Price :
$35
*
At a glance
- Drugs Quetiapine (Primary)
- Indications Depression; Major depressive disorder
- Focus Therapeutic Use
- Acronyms AMETHYST
- Sponsors AstraZeneca
- 31 Jul 2012 Results published in the International Clinical Psychopharmacology.
- 16 Sep 2009 Results of a secondary analysis investigating the effects of quetiapine on functioning and sleep quality have been presented at the 22nd Annual Congress of the European College of Neuropsychopharmacology.
- 03 May 2008 Results have been presented at the 161st Annual Meeting of the American Psychiatric Association.